These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32160389)

  • 1. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
    Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
    J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
    West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring.
    West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
    J Pharm Biomed Anal; 2024 Mar; 240():115932. PubMed ID: 38198884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
    Ramgopal MN; Castagna A; Cazanave C; Diaz-Brito V; Dretler R; Oka S; Osiyemi O; Walmsley S; Sims J; Di Perri G; Sutton K; Sutherland-Phillips D; Berni A; Latham CL; Zhang F; D'Amico R; Pascual Bernáldez M; Van Solingen-Ristea R; Van Eygen V; Patel P; Chounta V; Spreen WR; Garges HP; Smith K; van Wyk J
    Lancet HIV; 2023 Sep; 10(9):e566-e577. PubMed ID: 37567205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
    Gouget H; Noé G; Barrail-Tran A; Furlan V
    J Pharm Biomed Anal; 2020 Mar; 181():113057. PubMed ID: 31962247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
    Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
    J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma.
    Schauer AP; Sykes C; Cottrell ML; Imaz A; Podzamczer D; Kashuba AD
    J Pharm Biomed Anal; 2022 Oct; 220():115010. PubMed ID: 36030752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS.
    Rigo-Bonnin R; Tiraboschi JM; Álvarez-Álvarez M; Pérez-Fernández GA; Sanjuás-Iglesias M; Scévola S; Niubó J; Videla S; Podzamczer D
    J Pharm Biomed Anal; 2020 Jun; 185():113250. PubMed ID: 32199329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
    Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
    J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues.
    Ramöller IK; Abbate MTA; Vora LK; Hutton ARJ; Peng K; Volpe-Zanutto F; Tekko IA; Moffatt K; Paredes AJ; McCarthy HO; Donnelly RF
    J Pharm Biomed Anal; 2022 May; 213():114698. PubMed ID: 35259714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV.
    Thoueille P; Seybold U; Decosterd LA; Desfontaine V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jan; 1214():123575. PubMed ID: 36542988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
    Courlet P; Spaggiari D; Desfontaine V; Cavassini M; Alves Saldanha S; Buclin T; Marzolini C; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1125():121733. PubMed ID: 31374423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
    Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
    Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
    Rajoli RKR; Curley P; Chiong J; Back D; Flexner C; Owen A; Siccardi M
    J Infect Dis; 2019 May; 219(11):1735-1742. PubMed ID: 30566691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring.
    West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123905. PubMed ID: 37866010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
    Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
    Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
    Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.